- Commods, Banks Drag Euro Stocks Down
- European Stocks to Open Sharply Lower
- Toshiba to Briefly Halt Chip Output on Weak Demand
- Boeing Mulls Pushing Back Dreamliner Deliveries
- Chief Executive Quits Australian Publisher Fairfax
- Asian Markets Wobble on Gloomy Economic Outlook
- Motor Racing-Honda Pulls Out of Formula One
- Job Cuts Picking Up Steam Just in Time for Holidays
- Pros Say: Bear Market Rallies = New Reality
- Wall of Shame: Fortress Investment's Wes Edens
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
- Toll Brothers CEO's Housing Outlook
- Making Money Off M&A
- Your First Move For Friday December 5th
- Web Extra: Fast & Furious Trades For Friday
- AP IMPACT: Some bailout holdings down $9 billion
- Proposed fee on smelly cows, hogs angers farmers
- Malaysia's Proton to build new car with Mitsubishi
- ADB lends $500 mln to clean up dirtiest river
- Tough economy forces many US Muslims delay hajj
- Mexico wants to shrink coins to save a few cents
- Mexican Senate passes stricter credit rules
- US, China promise $20 billion to finance trade
- Cemex: World Bank unit to hear Venezuela dispute
- Philippines' inflation eases for 3rd month
Text Size 
NEW YORK - French drugmaker Sanofi-Aventis SA is cutting an unspecified number of U.S. sales jobs as part of a realignment of its marketing.
The company said in an e-mailed statement that it is realigning its sales force. The changes, it said, would affect a single-digit percentage of its 6,500-person U.S. sales force, implying jobs cuts of fewer than 650.
Sanofi said in the statement that the moves are part of "a new commercial model designed to deliver greater value to our customers in a rapidly changing business environment."
The company, whose U.S. headquarters is in Bridgewater, N.J., did not say which locations the cuts are affecting.
The cuts follow on similar moves made by other drugmakers, including GlaxoSmithKline, Novartis and Merck, as they try to cut costs and improve sales amid increasing competition from cheaper generic drugs, more pressure from payers to hold down prices and other challenges.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes